A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Locations

Germany

Start date

30/04/2026

Identifiers

Trial ID NN9833-8421,
NCT number NCT07557953,
Eudract number Not Available

Summary

The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is the treatment being tested, while placebo looks like the study medicine but does not contain any active medicine. The study will last for about 30 weeks.

Trial Overview:

Condition

Overweight

Obesity

Treatment

DRUG: Cagrilintide

DRUG: Placebo Cagrilintide

Study type

INTERVENTIONAL

Trial duration

Apr 30 2026 - Apr 13 2027

Participants

120

Phase

Are you eligible?

Gender

Male and female

Age

18 to 64 years old

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.